Shire's Says Xiidra 5% is Now Available in U.S.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Shire's First Prescription Eye Drop, Xiidra™ (lifitegrast ophthalmic solution) 5% is Now Available in the U.S.
August 29, 2016 10:48 AM EDTLEXINGTON, Massachusetts, August 29, 2016 /PRNewswire/ --
Xiidra is the only prescription eye drop approved by the U.S. FDA for the treatment of both signs and symptoms of dry eye disease  Resources are available to support patients seeking information regarding coverage and savings offers  Xiidra is the first medication in a new class of drugs - a lymphocyte function-associated antigen 1 (LFA-1) antagonist - approved by the FDA for dry eye diseaseÂShire plc (LSE: SHP, NASDAQ: SHPG) today announced that Xiidra... More
